Tetrahydrocannabutol

CB1 agonism produces tachycardia and transient hypotension. In patients with unstable cardiovascular conditions (arrhythmias, recent myocardial infarction, heart failure), these hemodynamic effects may precipitate adverse cardiac events. THCB's partial agonist status may attenuate maximal cardiovascular effects, but this is unconfirmed.

CB1 receptor agonism is a recognized risk factor for precipitating acute psychotic episodes in individuals with schizophrenia spectrum or schizoaffective disorders. THCB's partial CB1 agonist activity is sufficient to trigger this risk. No THCB-specific data; inferred from Δ9-THC class membership.

Individuals with a first-degree relative affected by schizophrenia or other psychotic disorders carry elevated genetic risk for cannabinoid-precipitated psychosis. CB1 agonism — even partial — may unmask latent psychotic vulnerability in these individuals.

If THCB is metabolized by hepatic CYP2C9 analogous to Δ9-THC, patients with hepatic impairment would experience reduced clearance, prolonged duration, and increased exposure. This could heighten both desired and adverse effects. The metabolic pathway is inferred, not confirmed.

Δ9-THC crosses the placenta and is excreted in breast milk, with documented associations with reduced fetal growth and potential neurodevelopmental effects. THCB, as a structurally homologous CB1 partial agonist, is expected to share these properties. No THCB-specific reproductive toxicity data exist.

Δ9-THC and analogs competitively inhibit CYP2C9, the primary enzyme metabolizing warfarin. THCB is predicted to share this inhibitory profile based on structural homology. Co-administration could elevate warfarin plasma levels and increase bleeding risk. No THCB-specific CYP inhibition data exist.

Δ9-THC inhibits CYP3A4. THCB is predicted to share this property. Co-administration with narrow-therapeutic-index CYP3A4 substrates such as tacrolimus, cyclosporine, and certain antiepileptics (carbamazepine, clobazam) could produce clinically dangerous elevations in their plasma concentrations. No THCB-specific data.